Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast Cancer

Video

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.

In the PERSEPHONE trial, the investigators looked at disease-free survival in women with early-stage HER2-positive breast cancer who would need adjuvant trastuzumab (Herceptin). Twelve months of adjuvant trastuzumab was compared with 6 months of adjuvant trastuzumab to assess whether 9 doses was noninferior to 18 doses, says Shafaee.

The trial reported noninferiority with 6 months of adjuvant trastuzumab, which has a very high clinical impact, explains Shafaee. Shafaee recently saw a patient with mild cardiomyopathy who was being treated with adjuvant trastuzumab. The patient’s ejection fraction recovered, following 9 doses of trastuzumab. Following the results of the trial, they considered stopping therapy after 9 doses. Shafaee underscores that this is not yet included in the NCCN guidelines, so more data are needed before straying from the current standard 12 months of therapy.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "